Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Description:
Host: Matthew S. Davids, MD, MMSc
This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert gu...